Tom Powles presents a new standard of care for frontline bladder cancer: Enfortumab Vedotin + Pembrolizumab reduces risk of death by 53% compared to chemo👏🏻 EV302 results today at #ESMO23 well done to all involved and thank you to all patients + families who made this possible

It’s an honour to be part of the Avenue Calgary Magazine Top 40 Under 40. Thank you to my patients, family, and all who have supported me, particularly Lara and Daniel Heng Alberta Health Services albertacancer OWN.CANCER avenuecalgary.com/top-40-under-4…

Congratulations to one of our medoncs Steve Yip, MD, MSc for achieving the Top 40 under 40 this year!!! Thanks for all you do for our patients and for helping to build transformative programs in precision oncology. Proud of you! Alberta Health Services UCalgaryMedicine avenuecalgary.com/top-40-under-4…

💫🌟 MUST READ!👩‍⚕️👨‍⚕️ 📚🔝Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the #InternationalMetastaticRenalCellCarcinomaDatabaseConsortium BY Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, J. Connor Wells, @

At #JSMO with 3 controversies from ASCOGU 1) The -ve OS adjuvant pembro data in UC questions this approach more broadly. Censoring ++ on KM curve though. 2) More data needed to prove atezo is active with cabo in CRPC. 3)Ipi/nivo looks as good as anything else in good risk M1 RCC

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…

JUST IN: U.S. FDA approves nogapendekin alfa inbakicept-pmln with (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Data based on QUILT-3.032 (NCT0302285). Full details here: fda.gov/drugs/resource…

Come see our #IMDC fellow @Martinzarba Saturday 8am Room S100bc present on the Favorable risk and VERY favorable risk metastatic #kidneycancer population for potential guidance on therapy selection. #IMDConline Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Tom Powles Ravindran Kanesvaran OncoAlert #ASCO24

Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinations Kosuke Takemura Daniel Heng bmjoncology.bmj.com/content/3/1/e0…

Many oncologists are more familiar with ‘traditional’ investigator-reported endpoints, like objective response rate, progression-free survival and OS but probably less familiar with the correct reading and interpretation of quality of life results. bmjoncology.bmj.com/content/3/1/e0…

The Uromigos Live and unplugged has come to an end. Finally we won the silver medal 🥈　I will push forward in GU oncology so that we can win a gold medal next time. Many thanks to Tom and Brian! And to many friends!

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-rel…

Treatment free survival is becoming an important endpoint when looking at different #mRCC treatments. VEGF alone had shortest TFS. Something to be said about treatment breaks. Thx to #mehulgupta and #meredithregan IMDC Rana McKay, MD, FASCO Tom Powles Toni Choueiri, MD European Urology Oncology

Many thanks Danny - it was such a great reunion! See you next year #GU25 #imdc

Proud to be part of the collaboration:) Thanks for the perfect management Fumihiko Urabe